{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T03:12:31Z","timestamp":1765422751617,"version":"3.46.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,10]]},"DOI":"10.7759\/cureus.98931","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T03:08:49Z","timestamp":1765422529000},"source":"Crossref","is-referenced-by-count":0,"title":["Pembrolizumab-Induced Aplastic Anemia Successfully Treated With Thrombopoietin Receptor Agonist in a Patient With Lung Adenocarcinoma: A Case Report and Literature Review"],"prefix":"10.7759","author":[{"given":"Kensuke","family":"Namba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutoshi","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanshiro","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Hiruta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04690-x","article-title":"Current challenges of hematologic complications due to immune checkpoint blockade: a comprehensive review","volume":"101","author":"Ghanem P","year":"2022","unstructured":"Ghanem P, Marrone K, Shanbhag S, Brahmer JR, Naik RP. Current challenges of hematologic complications due to immune checkpoint blockade: a comprehensive review. Ann Hematol. 2022, 101:1-10. 10.1007\/s00277-021-04690-x","journal-title":"Ann Hematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009016","article-title":"Hematologic complications of immune checkpoint inhibitors","volume":"139","author":"Kroll MH","year":"2022","unstructured":"Kroll MH, Rojas-Hernandez C, Yee C. Hematologic complications of immune checkpoint inhibitors. Blood. 2022, 139:3594-604. 10.1182\/blood.2020009016","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0574","article-title":"Hematologic complications of immune checkpoint inhibitors","volume":"24","author":"Davis EJ","year":"2019","unstructured":"Davis EJ, Salem JE, Young A, et al.. Hematologic complications of immune checkpoint inhibitors. Oncologist. 2019, 24:584-8. 10.1634\/theoncologist.2018-0574","journal-title":"Oncologist"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109965","article-title":"Eltrombopag added to immunosuppression in severe aplastic anemia","volume":"386","author":"Peffault de Latour R","year":"2022","unstructured":"Peffault de Latour R, Kulasekararaj A, Iacobelli S, et al.. Eltrombopag added to immunosuppression in severe aplastic anemia. N Engl J Med. 2022, 386:11-23. 10.1056\/NEJMoa2109965","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13853","article-title":"Guidelines for the diagnosis and management of adult aplastic anaemia","volume":"172","author":"Killick SB","year":"2016","unstructured":"Killick SB, Bown N, Cavenagh J, et al.. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016, 172:187-207. 10.1111\/bjh.13853","journal-title":"Br J Haematol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1057134","article-title":"Immune checkpoint inhibitor-induced aplastic anaemia: case series and large-scale pharmacovigilance analysis","volume":"14","author":"Guo Q","year":"2023","unstructured":"Guo Q, Zhao JN, Liu T, Gao J, Guo H, Cheng JM. Immune checkpoint inhibitor-induced aplastic anaemia: case series and large-scale pharmacovigilance analysis. Front Pharmacol. 2023, 14:1057134. 10.3389\/fphar.2023.1057134","journal-title":"Front Pharmacol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.04.004","article-title":"Immune-related bone marrow failure following anti-PD1 therapy","volume":"80","author":"Michot JM","year":"2017","unstructured":"Michot JM, Vargaftig J, Leduc C, et al.. Immune-related bone marrow failure following anti-PD1 therapy. Eur J Cancer. 2017, 80:1-4. 10.1016\/j.ejca.2017.04.004","journal-title":"Eur J Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/0300891619856197","article-title":"Unexpected serious aplastic anemia from PD-1 inhibitors: beyond what we know","volume":"105","author":"Filetti M","year":"2019","unstructured":"Filetti M, Giusti R, Di Napoli A, Iacono D, Marchetti P. Unexpected serious aplastic anemia from PD-1 inhibitors: beyond what we know. Tumori. 2019, 105:NP48-51. 10.1177\/0300891619856197","journal-title":"Tumori"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1159\/000495980","article-title":"Nivolumab induced lethal aplastic anemia in a patient with metastatic melanoma","volume":"12","author":"Rouvinov K","year":"2019","unstructured":"Rouvinov K, Nalbandyan K, Kozlov V, Peled N, Yakobson A. Nivolumab induced lethal aplastic anemia in a patient with metastatic melanoma. Case Rep Oncol. 2019, 12:29-32. 10.1159\/000495980","journal-title":"Case Rep Oncol"},{"key":"ref10","doi-asserted-by":"crossref","DOI":"10.3897\/biodiscovery.22.e37211","article-title":"Aplastic anemia induced by nivolumab before a treatment of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia","volume":"22","author":"Cheng W","year":"2019","unstructured":"Cheng W, Jackson B. Aplastic anemia induced by nivolumab before a treatment of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. BioDiscovery. 2019, 22:e37211.","journal-title":"BioDiscovery"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217726159","article-title":"Nivolumab-induced aplastic anemia: a case report and literature review","volume":"25","author":"Comito RR","year":"2019","unstructured":"Comito RR, Badu LA, Forcello N. Nivolumab-induced aplastic anemia: a case report and literature review. J Oncol Pharm Pract. 2019, 25:221-5. 10.1177\/1078155217726159","journal-title":"J Oncol Pharm Pract"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1159\/000500856","article-title":"AIHA and pancytopenia as complications of pembrolizumab therapy for metastatic melanoma: a case report","volume":"12","author":"Ni D","year":"2019","unstructured":"Ni D, AlZahrani F, Smylie M. AIHA and pancytopenia as complications of pembrolizumab therapy for metastatic melanoma: a case report. Case Rep Oncol. 2019, 12:456-65. 10.1159\/000500856","journal-title":"Case Rep Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2020.100686","article-title":"A case of non-small cell lung cancer with danazol-dependent aplastic anemia induced by pembrolizumab","volume":"45","author":"Goda S","year":"2021","unstructured":"Goda S, Tsuji T, Matsumoto Y, et al.. A case of non-small cell lung cancer with danazol-dependent aplastic anemia induced by pembrolizumab. Curr Probl Cancer. 2021, 45:100686. 10.1016\/j.currproblcancer.2020.100686","journal-title":"Curr Probl Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx177","article-title":"Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma","volume":"28","author":"Helgadottir H","year":"2017","unstructured":"Helgadottir H, Kis L, Ljungman P, et al.. Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma. Ann Oncol. 2017, 28:1672-3. 10.1093\/annonc\/mdx177","journal-title":"Ann Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-018-0098-5","article-title":"Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report","volume":"7","author":"Meyers DE","year":"2018","unstructured":"Meyers DE, Hill WF, Suo A, Jimenez-Zepeda V, Cheng T, Nixon NA. Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report. Exp Hematol Oncol. 2018, 7:6. 10.1186\/s40164-018-0098-5","journal-title":"Exp Hematol Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-021-00616-4","article-title":"Aplastic anemia secondary to dual cancer immunotherapies a physician nightmare: case report and literature review","volume":"17","author":"Younan RG","year":"2021","unstructured":"Younan RG, Raad RA, Sawan BY, Said R. Aplastic anemia secondary to dual cancer immunotherapies a physician nightmare: case report and literature review. Allergy Asthma Clin Immunol. 2021, 17:112. 10.1186\/s13223-021-00616-4","journal-title":"Allergy Asthma Clin Immunol"},{"key":"ref17","article-title":"[Adenocarcinoma with aplastic anemia as an immune-related adverse event caused by pembrolizumab: report of a case]","volume":"77","author":"Hashimoto S","year":"2024","unstructured":"Hashimoto S, Haga N, Morimoto M, Doi Y. [Adenocarcinoma with aplastic anemia as an immune-related adverse event caused by pembrolizumab: report of a case]. Kyobu Geka. 2024, 77:235-8.","journal-title":"Kyobu Geka"},{"key":"ref18","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V85.5.1348.bloodjournal8551348","article-title":"Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study of the EBMT SAA Working Party","volume":"85","author":"Bacigalupo A","year":"1995","unstructured":"Bacigalupo A, Broccia G, Corda G, et al.. Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study of the EBMT SAA Working Party. Blood. 1995, 85:1348-53.","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/428070-pembrolizumab-induced-aplastic-anemia-successfully-treated-with-thrombopoietin-receptor-agonist-in-a-patient-with-lung-adenocarcinoma-a-case-report-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T03:09:00Z","timestamp":1765422540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/428070-pembrolizumab-induced-aplastic-anemia-successfully-treated-with-thrombopoietin-receptor-agonist-in-a-patient-with-lung-adenocarcinoma-a-case-report-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.98931","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,10]]}}}